Filing Details

Accession Number:
0001127602-21-028263
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-03 16:11:56
Reporting Period:
2021-11-01
Accepted Time:
2021-11-03 16:11:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1628884 L. Julie Gerberding Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth NJ 07033
Evp, Chief Patient Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-01 35,287 $0.00 74,449 No 4 M Direct
Common Stock Acquisiton 2021-11-01 30,175 $0.00 104,624 No 4 M Direct
Common Stock Acquisiton 2021-11-01 19,394 $0.00 124,018 No 4 M Direct
Common Stock Acquisiton 2021-11-01 11,414 $0.00 135,432 No 4 M Direct
Common Stock Disposition 2021-11-01 96,270 $87.91 39,162 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-11-01 35,287 $0.00 35,287 $62.07
Common Stock Stock Option (Right to Buy) Disposition 2021-11-01 30,175 $0.00 30,175 $56.04
Common Stock Stock Option (Right to Buy) Disposition 2021-11-01 19,394 $0.00 19,394 $77.62
Common Stock Stock Option (Right to Buy) Disposition 2021-11-01 11,414 $0.00 11,414 $75.36
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-05-05 2027-05-04 No 4 M Direct
0 2019-05-04 2028-05-03 No 4 M Direct
9,698 2020-05-03 2029-05-02 No 4 M Direct
22,831 2021-05-01 2030-04-30 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.9050 to $87.9250, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  2. Holdings include shares acquired in dividend reinvestment transactions.
  3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
  4. The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
  5. The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.
  6. The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
  7. The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.